The device was not returned for analysis.A review of the lot history record (lhr) and corrective action tracking system for the web (catsweb) database for the reported lot could not be performed as the lot number and part number are unknown.Based on the information reviewed, and due to limited information available from the article the cause for the reported bleeding, cerebrovascular accident, transient ischemic attack, and myocardial infarction (mi) could not be determined.Additionally, the reported patient effects of bleeding, cerebrovascular accident, transient ischemic attack, and myocardial infarction (mi) are listed in the instructions for use, and are known possible complications associated with mitraclip procedures.The reported medical intervention was the result of case-specific circumstances.There is no indication of a product quality issue with respect to manufacture, design, or labeling.B3: date of event estimated.D4: the udi is unknown due to the part/lot number was not provided.D6: date of implant estimated.Attachment: article titled ¿bleeding and thrombotic risk of different antiplatelet regimens posttranscatheter edge-to-edge mitral valve repair in patients with an indication for oral anticoagulation: results from an all-comers national registry.¿.
|
It was reported through a research article that 322 patients underwent transcatheter edge-to-edge mitral valve repair (teer) from 2011 to 2021.Within 3 months of the procedure, the implanted mitraclip may have caused or contributed to bleeding, blood transfusion, stroke, transient ischemic attack (tia) and myocardial infarction (mi).Additional information is listed in the attached article, titled, ¿bleeding and thrombotic risk of different antiplatelet regimens posttranscatheter edge-to-edge mitral valve repair in patients with an indication for oral anticoagulation: results from an all-comers national registry.¿.
|